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Abstract: Hydrochloric acid (HCl) exposure causes asthma-like conditions, reactive airways dysfunction syndrome, and pulmonary fibrosis. Heat Shock Protein 90 (HSP90) is a molecular chaperone that
regulates multiple cellular processes. HSP90 inhibitors are undergoing clinical trials for cancer and are
also being studied in various pre-clinical settings for their anti-inflammatory and anti-fibrotic effects.
Here we investigated the ability of the heat shock protein 90 (HSP90) inhibitor AT13387 to prevent
chronic lung injury induced by exposure to HCl in vivo and its protective role in the endothelial
barrier in vitro. We instilled C57Bl/6J mice with 0.1N HCl (2 µL/g body weight, intratracheally) and
after 24 h began treatment with vehicle or AT13387 (10 or 15 mg/kg, SC), administered 3×/week; we
analyzed histological, functional, and molecular markers 30 days after HCl. In addition, we monitored transendothelial electrical resistance (TER) and protein expression in a monolayer of human
lung microvascular endothelial cells (HLMVEC) exposed to HCl (0.02 N) and treated with vehicle or
AT13387 (2 µM). HCl provoked persistent alveolar inflammation; activation of profibrotic pathways
(MAPK/ERK, HSP90); increased deposition of collagen, fibronectin and elastin; histological evidence
of fibrosis; and a decline in lung function reflected in a downward shift in pressure–volume curves,
increased respiratory system resistance (Rrs), elastance (Ers), tissue damping (G), and hyperresponsiveness to methacholine. Treatment with 15 mg/kg AT13387reduced alveolar inflammation, fibrosis,
and NLRP3 staining; blocked activation of ERK and HSP90; and attenuated the deposition of collagen
and the development of chronic lung injury and airway hyperreactivity. In vitro, AT13387 prevented
HCl-induced loss of barrier function and AKT, ERK, and ROCK1 activation, and restored HSP70 and
cofilin expression. The HSP90 inhibitor, AT13387, represents a promising drug candidate for chronic
lung injury that can be administered subcutaneously in the field, and at low, non-toxic doses.
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Heat Shock Proteins (HSPs) are molecular chaperones that assist the folding, stabilization and activity, but when necessary also participate prominently in the degradation, of a
high number of “client proteins” [1]. The HSP family consists of multiple proteins with specific and diverse functions, classified by molecular weight. Heat Shock Protein 90 (HSP90)
is the most abundant of these proteins, comprising 1–2% of the overall cellular proteins
under basal conditions, and able to reach 5–10% during stress. HSP90 stabilizes folded
proteins, thus promoting the proper signaling of crucial pathways involved in cell survival
from environmental stressors such as hypoxia, high temperature, and oxidative stress [2].
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Recent reports suggest that by disrupting protein stability and blocking specific cellular
responses, HSP90 inhibition may represent a novel therapeutic approach to pulmonary
fibrosis [3,4].
HCl is a chemical produced in massive quantities (20 million metric tons/year [5]) and
employed in oil, gas, and steel industries, in scientific laboratories, and in swimming pool
maintenance. Due to its wide use, spills occur frequently and cause accidental exposures.
In addition, HCl and its more volatile derivate, chlorine (Cl), have been utilized in chemical
warfare since World War II, and recently in the Syrian province of Aleppo, causing multiple
casualties [6]. Acutely, HCl evokes strong inflammation in the eyes and airways, with shortness of breath, difficulty in breathing and, depending on dose and duration of exposure,
acute respiratory distress syndrome (ARDS) and death [7,8]. Furthermore, after a single
exposure, a persistent mild inflammatory and pro-fibrotic response is observed, leading
to chronic injuries, such as reactive airways dysfunction syndrome (RADS), asthma-like
conditions, and pulmonary fibrosis [8–10].
There are no FDA-recommended drugs to prevent dangerous complications from HCl
exposure. We have previously reported that the HSP90 inhibitor AUY-922 prevented both
HCl and nitrogen mustard-induced long-term pulmonary injury and fibrosis [11,12]. These
beneficial effects have been observed by us and others, as HSP90 is a critical stabilizer of
transforming growth factor-β (TGF-β), the leading cytokine in pulmonary fibrosis [13,14].
AUY-922, however, requires intraperitoneal or intravenous administration and thus is
difficult to administer outside hospital settings. Therefore, we investigated the antidotal properties of a newer HSP90 inhibitor, AT13387 (also known as Onalespib), which
has a longer half-life [15] and can be administered subcutaneously in out-of-hospital,
emergency situations.
2. Materials and Methods
2.1. Materials
HCl, ACS grade, methacholine USP grade, RIPA buffer, and protease inhibitor cocktail
were obtained from Sigma-Aldrich Corporation (St. Louis, MO, USA). Socumb (pentobarbital) USP grade, Anased (xylazine) USP grade, and Ketaset (ketamine) USP grade were
supplied by Henry Schein Animal Health (Pittsburg, PA, USA). Formaldehyde (10%) was
purchased from Thermo Fisher Scientific (Waltham, MA, USA), the BCA Protein assay
kit from Pierce Co. (Rockford, IL, USA), EDTA and Western blot membranes from GE
Healthcare (Chicago, IL, USA), TRIzol and SuperScript VILO reverse transcriptase kit from
Invitrogen (Carlsbad, CA, USA), RNeasy Mini Kit from Qiagen (Hilden, Germany), and
SYBR Green Master Mix from Applied Biosystems (Carlsbad, CA, USA). All primers used
for real-time quantitative PCR were purchased from Integrated DNA Technologies, Inc.
(Coralville, IA, USA). SDS-PAGE, ProtoGel (30% acrylamide mix), and TEMED were from
National Diagnostics (Atlanta, GA, USA), Tris-HCl buffer from Teknova (Hollister, CA,
USA), 10% SDS and ammonium persulfate from Thermo Fisher Scientific, and Protein Dual
Color Standards and Tricine Sample Buffer from Bio-Rad Laboratories (Hercules, CA, USA).
All antibodies were purchased from reputable commercial sources and have published immunospecificity data. For antibodies used in Western blots, rabbit total and phosphorylated
(1:1000; ERK1/2, HSP90, HSP70, AKT, Cofilin, ROCK1), antibodies were obtained from
Cell Signaling Technology, Inc. (Danvers, MA, USA), mouse monoclonal anti-beta actin
from Sigma-Aldrich Corporation (1:1000), and IRDye 800CW Goat anti-rabbit and IRDye
680RD Goat anti-mouse antibodies (1:5000) from LI-COR Biosciences (Lincoln, NE, USA).
2.2. Ethical Statement
All animal studies were approved by Old Dominion University IACUC, adhere to the
principles of animal experimentation as published by the American Physiological Society,
and were carried out in Biosafety Level 2 (BSL-2) and Animal Biosafety Level 2 (ABSL-2)
facilities at the Frank Reidy Research Center for Bioelectrics in Norfolk, Virginia.
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2.3. Animals
Adult male C57Bl/6J mice (Jackson Laboratories, Bar Harbor, ME, USA; 8–10 weeks
old, 24–28 g body weight) were housed under pathogen-free conditions. Mice were intratracheally instilled with vehicle or HCl (0.1 N) and treated after 24 h with either vehicle
(10% DMSO in corn oil) or with the HSP90 inhibitor AT13387 (10 or 15 mg/kg). Mice were
then divided into four treatment groups: (1) mice that were exposed to the vehicle (saline),
(2) mice that were exposed to 0.1 N HCl and treated with the vehicle (10% DMSO in corn
oil) 3 times/week, (3) mice that were exposed to 0.1 N HCl and treated with AT13387
15 mg/kg, 3 times/week, and (4) mice that were exposed to 0.1 N HCl and treated with
AT13387, 10 mg/kg, 3 times/week. On day 0, the mice were anesthetized with intraperitoneal (i.p.) injections of xylazine (6 mg/kg) and ketamine (60 mg/kg). An i.p. bolus of
sterile normal saline (10 µL/g) was given as pre-emptive fluid resuscitation. After cleaning
and disinfecting the surgical field, a small neck skin incision (~1 cm) was made and the
salivary glands were separated to visualize the trachea. Mice were suspended vertically
from their incisors and a fine, (20–25 G) plastic catheter was advanced into the trachea
(~1.5 cm) in such a way that it could be seen through the walls of the trachea. Freshly
prepared HCl solution (groups 2–4) or sterile saline (group 1) was instilled (2 µL/g body
weight) and flushed with 100 µL air. The catheter was withdrawn, the neck incision closed
by surgical adhesive Vetbond, and the animals were placed in the ventral position in a
small chamber on top of a heating pad under supplemental oxygen (slowly weaned from
100 to 21% O2 ) and observed for the next 4 h for signs of respiratory distress. Mice were
returned to their home-cages (five mice/cage) and monitored daily for abnormal physical
appearances. On day 30, they were either anesthetized for lung function measurements or
euthanized, and bronchoalveolar lavage fluid (BALF) and lungs were collected for protein
and mRNA analyses or fixed for histological analysis.
2.4. Bronchoalveolar Lavage Fluid (BALF) White Blood Cell Number and Total Protein Concentration
BALF was obtained by instilling and withdrawing sterile 1x PBS (1 mL) via a tracheal
cannula. The fluid was centrifuged at 2500× g for 10 min and the supernatant was aspirated
and stored at −80 ◦ C. The cell pellet was re-suspended in 1 mL sterile PBS. The total number
of white blood cells (WBC) was determined using a hemocytometer. For differential
cell counts, within one hour after collecting BALF, the samples were mixed gently and
the cell suspensions were spun onto glass slides using a Cytospin 4 centrifuge (Thermo
Fisher, Waltham, MA, USA) set at 300 rpm for 10 min. The slides were stained using
the May–Grunwald–Giemsa staining protocol (Differential Quick Staining Kit, Electron
Microscopy Sciences, Hatfield, PA, USA), and a coverslip was mounted. A minimum of
400 cells were identified and counted under light microscopy (Olympus BX-46, Tokyo,
Japan). After the fluid was centrifuged at 2500× g for 10 min, the supernatant was collected
for estimation of total protein. The total protein concentration was determined using a micro
bicinchoninic acid (BCA) Protein Assay Kit according to the manufacturer’s instructions.
2.5. Histopathology, Immunohistochemistry and Lung Fibrosis Scoring
The mice were euthanized and their lungs were fixed by intratracheal instillation.
A small transverse incision was made in the middle of the trachea, and the lungs were
instilled and inflated with 10% formaldehyde solution to a pressure of 15 cm H2 O through a
20 G catheter. The trachea was then ligated with sutures and the lungs were removed from
the thorax and placed in 10% formaldehyde solution for 72 h. Mid-transverse slices were
made from the formalin-fixed lung tissue samples and were embedded in paraffin. Sections
5 µm thick were prepared from the blocks and stained with Masson’s trichrome stain
and for NLRP3. The NLPR3 antibody was used at a dilution of 1:1280, and staining was
performed using a standard protocol with HRP conjugated secondary antibody. Ten slides
were stained, and ten slides were used as negative controls where the primary antibody
was omitted. Positive control tissue (mouse esophagus) stained positive. Ten randomly
selected fields from each slide were examined under 10× and 20× magnification. All the
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slides were scored according to the Ashcroft score method in order to estimate the severity
of pulmonary fibrosis [16]. The observer was blinded to the treatment.
2.6. Tissue Collection
Immediately after euthanasia, the chest was opened, blood was collected from the
heart through the right ventricle, and the pulmonary circulation was flushed out with
sterile PBS containing EDTA. The lungs were dissected from the thorax, snap-frozen in
liquid nitrogen, and kept at −80 ◦ C for later analysis.
2.7. Western Blot Analysis
Proteins in lung tissue homogenates were extracted from frozen lungs by sonication
(50% amplitude, 3 times for 10 s) in ice-cold RIPA buffer with added protease inhibitor
cocktail (100:1). The protein lysates were gently mixed under agitation for 3 h at 4 ◦ C, and
then centrifuged twice at 14,000× g for 10 min. The supernatants were combined, and
total protein concentration was determined using the micro-BCA assay. Equal amounts
of protein from all lysates were used for Western blot analysis. The samples were first
mixed with Tricine Sample Buffer 1:1, then boiled for 5 min, then separated on a 10–12%
polyacrylamide SDS gel by electrophoresis. Separated proteins were then transferred to a
nitrocellulose membrane and incubated with the appropriate primary antibody, followed
by incubation with the secondary antibody and detection by digital fluorescence imaging
(LI-COR Odyssey CLx, Dallas, TX, USA). Beta-actin was used as the loading control.
ImageJ software v.1.8.0 was used to perform densitometric quantification of the bands (http:
//imagej.nih.gov/ij (accessed on 20 June 2021); National Institutes of Health, Bethesda,
MD, USA). For ERK and p-ERK, both bands were quantified together. Membranes were
stripped in a stripping buffer for 20 min, blocked, and incubated with other primary and
secondary antibodies.
2.8. RNA Isolation and Quantitative Real-Time PCR (qPCR)
Lung tissue, stored in an RNAlater solution, was dried and homogenized in TRIzol®
(Invitrogen, Carlsbad, CA, USA) followed by a cleaning step using the RNeasy Mini Kit.
The purified RNA was transcribed into cDNA using the SuperScriptTM IV VILO Reverse
transcriptase kit (Invitrogen, Carlsbad, CA, USA) and was analyzed by real-time qPCR with
SYBR Green Master Mix on a StepOne Plus Real-Time PCR System (Applied Biosystems
v.2.3). The results were evaluated using the standard curve method and were expressed as
the fold of the control values, normalized to β-actin. Specifically designed primer pairs and
qPCR conditions were applied to selectively determine the expression of mouse β-actin,
fibronectin, collagen 1α2, and elastin, as previously described [17,18]. Fibronectin, elastin,
collagen 1α2, and β-actin primers were as follows: Fibronectin F: GAA GTC GCA AGG
AAA CAA GC; Fibronectin R: GTT GTA GGT GAA CGG GAG GA; elastin F: GGA GTT
CCC GGT GGA GTC TAT T; elastin R: ACC AGG AAT GCC ACC AAC ACC TG; Collagen
1α2 F: GAA GCA CGT CTG GTT TGG A; Collagen 1α2 R: ACT CGA ACG GGA ATC CAT
C; Beta actin F: 50-CCC CTG AGG AGC ACC GTG TG-30; and Beta-actin R: 50-ATG GCT
GGG GTG TTG AAG GT-30.
2.9. Lung Mechanics Measurements
The mice were anesthetized with pentobarbital (90 mg/kg, i.p.), tracheostomized with
a metal 1.2 mm (internal diameter) cannula, and connected to a FlexiVent small animal
ventilator (SCIREQ Inc., Montreal, QC, Canada), as previously published [19]. Ventilation
was performed at a tidal volume of 10 mL/kg and a respiratory rate of 150/min. A 15-min
stabilization period was allowed before any measurements began. Firstly, following a
deep inflation, resting static compliance (Cst, mean of three values) and pressure volume
relationships (PV curves) were estimated by stepwise increasing airway pressure to 30 cm
H2 O and then reversing the process. Both parameters reflect the intrinsic elasticity of the
lungs and are either reduced (Cst) or shifted to the right (PV curves) in fibrosis. Secondly,
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Snapshot-150 and Quick Prime-3 manoeuvres were performed. Respiratory system resistance (Rrs) and elastance (Ers), reflecting the behaviour of the entire respiratory system
(peripheral and conducting airways, chest wall, and parenchyma); Newtonian resistance
(Rn); tissue damping (G); inspiratory capacity (A); and the curvature of the PV loops (K)
reflecting resistance of the large, conducting airways, parenchymal stiffness, and changes
in inspiratory gas dynamics, were calculated, and are presented as a mean of 12 recordings.
2.10. Cell Culture and Protein Extraction
In-house harvested human lung microvascular endothelial cells (HLMVEC) were
maintained in M199 media supplemented with 20% FBS and antibiotics/antimycotics,
as described previously [20]. HLMVEC were cultured in 100 mm dishes until 90–95%
confluency. For AT13387 treatment, cells were incubated with either 2 µM AT13387 or
vehicle (saline) and after 4 h were exposed to HCl (0.02 N) for 1h before protein isolation. To stop the experiment, dishes were placed on ice and washed 3 times with ice-cold
PBS. PBS was removed, and ice-cold lysis buffer was added (RIPA with protease inhibitor
cocktail 1:100). Cells were scraped and the cell suspension was transferred to a microcentrifuge tube. Tubes were placed at 4 ◦ C for 30 min under continuous agitation. Protein
concentration was estimated by the BCA protein assay. Equal volumes of tricine buffer
with 2% 2-mercaptoethanol were added to samples containing equal amounts of protein.
Proteins were denatured by 10 min boiling at 100 ◦ C. Protein lysates were then analyzed by
Western blotting.
2.11. Endothelial Barrier Function
HLMVEC were seeded on electrode arrays (8W10E+), and endothelial barrier integrity
was estimated by the electric cell-substrate impedance sensing (ECIS) technique, using an
ECIS-Z theta instrument (Applied BioPhysics, New York, NY, USA). Experiments were
conducted when a stable resistance was reached and maintained above 800 W, as we have
previously published [21]. Experiments were performed in triplicates and repeated at least
three times. Resistance values were collected and normalized to each well’s value at t = 0.
Data are presented as means ± SEM.
2.12. Statistical Analysis
The results are presented as means ± standard error of the mean. Statistical significance of differences among groups was determined by one- or two-way analysis of variance
(ANOVA), followed by the Tukey’s post-hoc test. Statistical analysis utilized GraphPad
Prism Software (GraphPad Software, San Diego, CA, USA). The significance level was set
at 0.05.
3. Results
3.1. AT13387 Modulates HCl-Induced Persistent Alveolar Inflammation
HCl produced persistent alveolar inflammation characterized by increased cellularity,
proteinosis, and inflammatory cytokines, consistent with previously published results [10].
Treatment with 15 mg/kg AT13387, but not 10 mg/kg, significantly reduced WBC infiltration to control levels (Figure 1A). However, both 10 and 15 mg/kg AT13387 were able to
reduce alveolar proteinosis (Figure 1B) and transforming growth factor-β (TGF-β) levels in
BALF (Figure 1C).
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to ββ-actin.
Relative(C)
expression
levelsby
of Fibronectin
and Elastin
(E)bands
mRNA were
analyzed
by RT-PCR.
actin. Relative expression
levels
of Fibronectin
and***:Elastin
(E)
mRNA
were analyzed
n = 4–5 mice
per group;
*: p < 0.05; **:(D)
p < 0.01,
p < 0.001,
with
1-way ANOVA
and Tukey’s.by RTPCR. n = 4–5 mice per group; *: p < 0.05; **: p < 0.01, ***: p < 0.001, with 1-way ANOVA and Tukey’s.

3.4. AT13387 Prevents HCl-Induced Lung Dysfunction and Airway Hyper-Responsiveness
to Methacholine

3.4. AT13387 Prevents Mice
HCl-Induced
Lung
Dysfunction
AirwayinHyper-Responsiveness
to
instilled with
HCl displayed
severe and
abnormalities
lung mechanics as measured
by
Flexivent.
HCl
produced
a
downward
shift
in
pressure–volume
relationships
(PV
loops)
Methacholine
indicative of airway dysfunction (Figure 4A) and increases in total respiratory system

Mice instilledresistance
with HCl
severe
abnormalities
lung
mechanics
as lung
meas(Rrs),displayed
tissue damping
(G), and
tissue elastancein
(H),
all signs
of increased
stiffness
(Figure
4B).
Treatment
with
AT13387,
at
either
10
or
15
mg/kg,
prevented
ured by Flexivent. HCl produced a downward shift in pressure–volume relationshipsthe(PV
downward shift in PV loops caused by HCl, while only treatment with the higher dose
loops) indicative of
airway dysfunction (Figure 4A) and increases in total respiratory syswas able to prevent increases in Rrs, G and H (Figure 4A,B). HCl is a well-known irritant
tem resistance (Rrs),
tissueairway
damping
(G), and tissue
elastance (H),
of increased
and caused
hyperresponsiveness
to methacholine,
whichall
wassigns
prevented
only by
treatment
with
AT13387
at
15
mg/kg
(Figure
4C).
lung stiffness (Figure 4B). Treatment with AT13387, at either 10 or 15 mg/kg, prevented
the downward shift in PV loops caused by HCl, while only treatment with the higher dose
was able to prevent increases in Rrs, G and H (Figure 4A,B). HCl is a well-known irritant
and caused airway hyperresponsiveness to methacholine, which was prevented only by
treatment with AT13387 at 15 mg/kg (Figure 4C).
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Figure 4. HCl causes lung dysfunction and airway hyperreactivity, blocked by AT13387.
Figure 4. HCl causes lung
dysfunction and airway hyperreactivity, blocked by AT13387. (A) Pres(A) Pressure–Volume relationships in mice after HCl instillation and treatment with vehicle or
sure–Volume relationships
afteratHCl
withResistance
vehicle (Rrs),
or AT13387
s.c.
AT13387in
s.c.mice
3×/week
10 or instillation
15 mg/kg. (B) and
Total treatment
Respiratory System
tissue
3×/week at 10 or 15 mg/kg.
Respiratory
System
(Rrs),
damping
(G), and
damping(B)
(G), Total
and tissue
elastance (H). (C)
Rrs and Resistance
total Respiratory
Systemtissue
Elastance
(Ers) were also
evaluated
in
response
to
increasing
concentrations
of
aerosolized
methacholine.
All
studies
were
tissue elastance (H). (C) Rrs and total Respiratory System Elastance (Ers) were also evaluated in
performed at 30 days after HCl instillation. n = 4–5 mice per group; ns: not significant, *: p < 0.05;
response to increasing**:concentrations
of aerosolized methacholine. All studies were performed at
p < 0.01, ****: p < 0.0001 with 2-way ANOVA and Bonferroni’s post-test (A), (C) or 1-way ANOVA
30 days after HCl instillation.
n(B).
= 4–5 mice per group; ns: not significant, *: p < 0.05; **: p < 0.01, ****:
and Tukey’s
p < 0.0001 with 2-way ANOVA and Bonferroni’s post-test (A), (C) or 1-way ANOVA and Tukey’s
3.5. AT13387 Prevents HCl-Mediated Endothelial Barrier Dysfunction
(B).

Treatment with AT13387 was able to prevent HCl-mediated alveolar proteinosis at 30
days post-instillation, in vivo (Figure 1B). Thus, we investigated if this effect was related
only
to the anti-inflammatory/anti-fibrotic
profile
of AT13387, or, similarly to other HSP90
3.5. AT13387 Prevents
HCl-Mediated
Endothelial Barrier
Dysfunction
inhibitors, to a direct effect on endothelial barrier function [21]. Indeed, AT13387 (2 µM)
Treatment withprevented
AT13387
was
able to prevent
HCl-mediated
alveolar
proteinosis
at
the loss
of endothelial
barrier integrity
provoked by 0.02
N HCl (Figure
5A).
AT13387 further prevented HCl-induced phosphorylation of ERK and AKT, with conse30 days post-instillation, in vivo (Figure 1B). Thus, we investigated if this effect was requent mobilization of cytoskeletal proteins ROCK1 (Figure 5C). These effects were assolated only to the anti-inflammatory/anti-fibrotic
AT13387,
or,and
similarly
ciated with AT13387-mediated increasedprofile
levels ofof
HSP70
(Figure 5B)
preventionto
of other
HSP70 decrease
and cofilin dephosphorylation
(Figure
5B,D).
HSP90 inhibitors, toHCl-induced
a direct effect
on endothelial
barrier function
[21].
Indeed, AT13387

(2µM) prevented the loss of endothelial barrier integrity provoked by 0.02N HCl (Figure
5A). AT13387 further prevented HCl-induced phosphorylation of ERK and AKT, with
consequent mobilization of cytoskeletal proteins ROCK1 (Figure 5C). These effects were
associated with AT13387-mediated increased levels of HSP70 (Figure 5B) and prevention
of HCl-induced HSP70 decrease and cofilin dephosphorylation (Figure 5 B,D).
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In this study, we investigated the use of a second-generation HSP90 inhibitor,
In this
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asstudy,
a potential
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against
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and pulmonary
fibrosis inas a potential antidote against chronic lung injury and pulmonary fibrosis induced by
duced by exposure to HCl. HSP90 inhibitors are FDA-approved drugs under clinical inexposure to HCl. HSP90 inhibitors are FDA-approved drugs under clinical investigation
vestigation for cancer, but many are being repurposed as novel therapeutics for lung, refor cancer, but many are being repurposed as novel therapeutics for lung, renal, hepatic,
nal,
and skin
fibrosis
[22–24].
In cancer
studies,
AT13387
has at
been
employed
andhepatic,
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translocation of Smad proteins, and inhibit Raf signaling, the non-canonical pathway of
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TGF-β
[22,30,31]. Other HSP90 inhibitors, AUY-922 and 17-AAG, were previously shown
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[32]. of
the extracellular matrix (ECM), thus reducing fibronectin deposition and tissue remodeling [32]. As shown by in vitro co-immunoprecipitation assay, HSP90 directly binds fibronectin and pharmacological or genetic HSP90 inhibition blocks fibronectin release from
cells [33]. In agreement, treatment with AT13387 resulted in reduced deposition of
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As shown by in vitro co-immunoprecipitation assay, HSP90 directly binds fibronectin and
pharmacological or genetic HSP90 inhibition blocks fibronectin release from cells [33]. In
agreement, treatment with AT13387 resulted in reduced deposition of collagen, fibronectin,
and elastin and greatly attenuated the histological evidence of fibrosis (Figure 2). The
inflammasome NLRP3 critically participates in IL-1β production during innate immune
response and lung injury. Treatment with AT13387 reduced NLRP3 expression in the lungs
(Figure 2).
HSP90 is a key regulator of alveolo-endothelial barrier function. The HSP90 inhibitor
17-AAG prevented LPS-induced endothelial hyperpermeability by blocking RhoA signaling
and consequent myosin light chain 2 activation (MLC2) [34]. We previously showed that
AUY-922 restored HCl-induced increased permeability by preventing RhoA activation and
cytoskeletal rearrangements [21]. Here we demonstrate that pre-treatment with AT13387
protects HLMVEC from an even higher dose of HCl (0.02N) by promoting HSP70 expression
and restoring cofilin function (Figure 5).
HSP70 acts as a co-chaperone of HSP90 and through the mediation of Hop/Stip
regulates proteostatic balance, redirecting damaged proteins to degradation [35]. HSP70
also exhibits important cytoprotective properties, as it reduces hypoxia/reoxygenation
injury [36], promotes cytoskeletal reassembly after gliadin exposure in a model of celiac
disease [37], and prevents humidity- and heat stress–mediated apoptosis in cardiomyocytes [38]. Intracellular HSP70 lies in the cytoplasm, where it forms a complex with heat
stress factor 1 (HSF-1) [39]. During HSP90 inhibition, HSF-1 is released, aggregated, and
translocated to the nucleus, where it binds DNA and promotes the expression of HSPs
through heat shock element (HSE) [40], thus explaining the collateral beneficial effects of
HSP70 overexpression [41].
The study has several limitations. Although we analyzed proteins and RNA expression
levels in lung tissue homogenates, cell population-based analysis could help better clarify
how HSP90 inhibitors exert their beneficial effect. Also, as AT13387 modulates several
pathways, proteomic studies could detect in vivo other target proteins that are involved
in the therapy of pulmonary fibrosis. Further, we identified how restoration of HSP70
in vitro, by AT13387, is associated with restoration of endothelial barrier function, but
further studies, in different animals’ models of lung injury (e.g., Bleomycin, LPS), are
required to understand the combined efficacy of HSP90 inhibitors, during overexpression
or inhibition of HSP70.
Most of the studies performed with HSP90 inhibitors use compounds that require
parenteral administration and short-acting half-life. Here, we presented evidence that
treatment with HSP90 inhibitor AT13387 (Onalespib) administered subcutaneously 3 times
per week dramatically prevented the long-term effects of HCl exposure, suggesting its use
in pre-hospital settings and disadvantageous situations.
5. Conclusions
HSP90 inhibitors represent a valid therapeutic approach for chronic lung injury and
employed at lower doses are beneficial for cancer. AT13387 can be administered subcutaneously and due to its long half-life represents an innovative countermeasure.
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